REGN1908-1909 Feld1 Antibody
REGN1908-1909
Feld1 Antibody
Allergic disease
A POWERFUL RESEARCH AND
DEVELOPMENT ENGINE
Our robust pipeline of investigational product candidates strives to address many serious medical conditions including asthma, pain, cancer and infectious diseases.
-
Phase 1 Trials
REGN2810*
REGN2810*
PD-1 AntibodyCancerREGN1979 CD20/CD3 Antibody
REGN1979
CD20XCD3 AntibodyCancer (also in combination with REGN2810)REGN3470-3471-3479 Antibody to Ebola virus
REGN3470-3471-3479
Antibody to Ebola virusEbola virus infectionREGN2477
REGN2477
Activin A AntibodyFibrodysplasia Ossificans Progressiva (FOP)TREVOGRUMAB GDF8 Antibody
TREVOGRUMAB
GDF8 Antibody(combination with REGN2477)REGN3500
REGN3500*
IL-33 AntibodyInflammatory diseasesREGN3767*
REGN3767*
LAG-3 AntibodyCancer -
Phase 1 Trials
TREVOGRUMAB
TREVOGRUMAB
GDF8 AntibodySkeletal muscle disordersDUPILUMAB* IL-4R Antibody
DUPILUMAB*
IL-4R AntibodyAtopic dermatitis in children, eosinophilic esophagitisSARILUMAB* IL-6R Antibody
SARILUMAB*
IL-6R AntibodyJuvenile idiopathic arthritisEVINACUMAB Angptl3 Antibody
EVINACUMAB
Angptl3 AntibodyHomozygous familial hypercholesterolemia, severe forms of hyperlipidemiaREGN910-3^ Nesvacumab (Ang2 Antibody) + Aflibercept
NESVACUMAB + AFLIBERCEPT^
Ang2 Antibody + AfliberceptWet age-related macular degeneration, diabetic macular edemaREGN2810* PD-1 Antibody
REGN2810*
PD-1 AntibodyAdvanced cutaneous squamous cell carcinoma -
Phase 1 Trials
ALIROCUMAB* PCSK9 Antibody
ALIROCUMAB*
PCSK9 AntibodyLDL cholesterol, cardiovascular eventsDUPILUMAB* IL-4R Antibody
DUPILUMAB*
IL-4R AntibodyAsthma and Nasal PolypsAFLIBERCEPT^ VEGF-Trap
AFLIBERCEPT
VEGF-TrapDiabetic retinopathy without diabetic macular edemaFASINUMAB† NGF Antibody
FASINUMAB†
NGF AntibodyPain due to osteoarthritisREGN2222 RSV Antibody
REGN2222
RSV AntibodyRespiratory syncytial virus infection
Trials Footnotes
* in collaboration with Sanofi
* in collaboration with Sanofi
^ in collaboration with Bayer HealthCare
^ in collaboration with Bayer HealthCare
† in collaboration with Teva and Mitsubishi Tanabe
† in collaboration with Teva and Mitsubishi Tanabe
This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.